Sharon Rosenzweig-Lipson, PhD will leverage decades of experience in R&D strategy and clinical development as Life Bio advances therapeutics that target the biology of aging.
Life Biosciences, a Boston-based life sciences company developing therapeutics that target the biology of aging, today announced the appointment of Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer. At Life Biosciences, she will be responsible for leading the company’s scientific research and development efforts built on the epigenetic reprogramming science of Dr David Sinclair and the chaperone-mediated autophagy discoveries of Dr Ana Maria Cuervo.
Longevity.Technology: A private biotech dedicated to discovering and developing novel therapies to improve the lives of people as they age, Life Biosciences is one of key players in commercialising the extension of healthy human lifespan. It is focusing on two platforms targeting key mechanisms underlying aging biology: epigenetic reprogramming to restore cellular function to a more youthful state and chaperone-mediated autophagy to reverse the age-related decline in the body’s ability to recycle unwanted proteins. Therapies developed within these platforms could have the potential to prevent, treat or even reverse multiple aging-related diseases.
“Dr Rosenzweig-Lipson brings great scientific and strategic leadership to Life Biosciences,” said Jerry McLaughlin, Chief Executive Officer at Life Biosciences.
“Sharon has been serving as a consultant to Life since early 2021 and has helped to create strong processes to accelerate our drug discovery and development. Her impressive background and accomplishments in both preclinical and clinical development will continue to be invaluable to us as we progress our therapies toward the clinic. It is a pleasure to officially welcome her to the team [1].”
Rosenzweig-Lipson holds significant expertise in screening strategies, in vivo models, translation and clinical development strategy, and she has more than three decades of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry and in biotech.
Her career in big pharma includes American Cyanamid, American Home Products, Wyeth, and Pfizer; most recently, as head of R&D, Rosenzweig-Lipson led the clinical development of AgeneBio’s lead asset through Phase 2B trials as well as the company’s preclinical development programs. She earned her BA in the biological basis of behavior from the University of Pennsylvania and her PhD in behavioral neuroscience from Harvard University.
“I am thrilled to be joining Life Biosciences to revolutionize the treatment of a wide-range of age-related disorders,” said Rosenzweig-Lipson. “I look forward to collaborating with the strong mission-driven team at Life Biosciences and its outstanding scientific collaborators [1].”
